PepGen (PEPG) Competitors $1.38 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.34 -0.03 (-2.54%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PEPG vs. SLS, ACRS, IMAB, TIL, PBYI, KYTX, DERM, BIOA, CCCC, and LFVNShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include SELLAS Life Sciences Group (SLS), Aclaris Therapeutics (ACRS), I-Mab (IMAB), Instil Bio (TIL), Puma Biotechnology (PBYI), Kyverna Therapeutics (KYTX), Journey Medical (DERM), BioAge Labs (BIOA), C4 Therapeutics (CCCC), and Lifevantage (LFVN). These companies are all part of the "pharmaceutical products" industry. PepGen vs. Its Competitors SELLAS Life Sciences Group Aclaris Therapeutics I-Mab Instil Bio Puma Biotechnology Kyverna Therapeutics Journey Medical BioAge Labs C4 Therapeutics Lifevantage SELLAS Life Sciences Group (NASDAQ:SLS) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Does the media prefer SLS or PEPG? In the previous week, PepGen had 22 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 25 mentions for PepGen and 3 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 1.29 beat PepGen's score of 0.13 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 0 Very Positive mention(s) 2 Positive mention(s) 22 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SLS or PEPG more profitable? PepGen's return on equity of -81.26% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences GroupN/A -193.67% -113.02% PepGen N/A -81.26%-63.65% Which has better valuation & earnings, SLS or PEPG? SELLAS Life Sciences Group has higher revenue and earnings than PepGen. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSELLAS Life Sciences Group$1M165.63-$30.88M-$0.38-4.37PepGenN/AN/A-$89.98M-$3.13-0.44 Do analysts recommend SLS or PEPG? SELLAS Life Sciences Group presently has a consensus price target of $7.00, indicating a potential upside of 321.69%. PepGen has a consensus price target of $7.67, indicating a potential upside of 455.56%. Given PepGen's higher possible upside, analysts clearly believe PepGen is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more volatility & risk, SLS or PEPG? SELLAS Life Sciences Group has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, PepGen has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Do insiders and institutionals believe in SLS or PEPG? 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 1.4% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 5.2% of PepGen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryPepGen beats SELLAS Life Sciences Group on 8 of the 14 factors compared between the two stocks. Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.15M$3.03B$5.63B$9.53BDividend YieldN/A2.39%4.71%4.04%P/E Ratio-0.4424.3630.2020.53Price / SalesN/A322.40455.8798.78Price / CashN/A42.5936.0158.40Price / Book0.388.278.355.74Net Income-$89.98M-$55.06M$3.25B$259.12M7 Day Performance-5.48%-3.96%-2.50%-3.41%1 Month Performance24.32%13.91%7.97%8.53%1 Year Performance-91.87%3.97%34.58%15.74% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen3.1981 of 5 stars$1.38flat$7.67+455.6%-92.1%$45.15MN/A-0.4430Gap UpSLSSELLAS Life Sciences Group2.3702 of 5 stars$1.85+4.5%$7.00+278.4%+38.5%$176.61M$1M-4.8710Options VolumeACRSAclaris Therapeutics1.9787 of 5 stars$1.64+1.9%$8.71+431.4%+16.5%$174.33M$18.72M-1.18100News CoverageUpcoming EarningsGap UpIMABI-Mab3.0128 of 5 stars$2.12+1.0%$6.00+183.0%+25.0%$171.49M$3.89M0.00380Positive NewsGap UpTILInstil Bio2.9054 of 5 stars$27.62+5.8%$119.00+330.8%+124.2%$171.19MN/A-2.31410Positive NewsPBYIPuma Biotechnology4.1466 of 5 stars$3.41+0.3%$7.00+105.3%-11.9%$168.74M$230.50M4.42200Positive NewsKYTXKyverna Therapeutics1.8543 of 5 stars$3.87-0.8%$18.50+378.0%-59.3%$168.55M$7.03M-1.1496News CoverageDERMJourney Medical2.1086 of 5 stars$7.19flat$9.50+32.1%+36.8%$167.50M$56.13M-18.4490News CoverageAnalyst ForecastBIOABioAge LabsN/A$4.60-0.6%N/AN/A$165.99M$1.45M0.00N/ACCCCC4 Therapeutics3.102 of 5 stars$2.27-2.2%$12.00+428.6%-65.6%$164.74M$35.58M-1.54150Gap UpLFVNLifevantage4.1158 of 5 stars$12.60-2.9%$30.50+142.1%+54.1%$163.27M$200.16M18.26260 Related Companies and Tools Related Companies SELLAS Life Sciences Group Alternatives Aclaris Therapeutics Alternatives I-Mab Alternatives Instil Bio Alternatives Puma Biotechnology Alternatives Kyverna Therapeutics Alternatives Journey Medical Alternatives BioAge Labs Alternatives C4 Therapeutics Alternatives Lifevantage Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PEPG) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Fed Just Froze You Out (Again)The Fed’s holding rates steady—again. No clarity. No yield. No relief. But one income strategy is quietly t...Investors Alley | SponsoredSomething BIG is about to hit the stock marketMost investors won’t see it coming—but Weiss Ratings says a major market event is brewing. Their system jus...Weiss Ratings | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PEPG Stock Alerts